Chester III - Revelation Biosciences Chief Officer
| REVB Stock | USD 0.76 0.01 1.33% |
Insider
Chester III is Chief Officer of Revelation Biosciences
| Age | 44 |
| Address | 4660 La Jolla Village Drive, San Diego, CA, United States, 92122 |
| Phone | 650 800 3717 |
| Web | https://www.revbiosciences.com |
Revelation Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.5098) % which means that it has lost $0.5098 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7002) %, meaning that it created substantial loss on money invested by shareholders. Revelation Biosciences' management efficiency ratios could be used to measure how well Revelation Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.01. The current year's Return On Capital Employed is expected to grow to -1.24. The current year's Intangible Assets is expected to grow to about 3.2 M, whereas Total Assets are forecasted to decline to about 11.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Lisa Miller | Lumos Pharma | N/A | |
| Carl Langren | Lumos Pharma | 69 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Richard Hawkins | Lumos Pharma | 75 | |
| James JD | Eliem Therapeutics | 58 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Hing Wong | HCW Biologics | 70 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| BBA CPA | Lumos Pharma | 57 | |
| Jeff York | Seres Therapeutics | N/A | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Lori CPA | Lumos Pharma | 40 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| David MBA | Seres Therapeutics | 63 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Peter Rhode | HCW Biologics | 66 | |
| Bradley JD | Lumos Pharma | 45 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
Management Performance
| Return On Equity | -2.7 | ||||
| Return On Asset | -0.51 |
Revelation Biosciences Leadership Team
Elected by the shareholders, the Revelation Biosciences' board of directors comprises two types of representatives: Revelation Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revelation. The board's role is to monitor Revelation Biosciences' management team and ensure that shareholders' interests are well served. Revelation Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revelation Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Rolke, CEO Director | ||
| Carol Odle, Director Projects | ||
| Chester III, Chief Officer | ||
| Sandra Vedrick, Vice Relations |
Revelation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revelation Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.7 | ||||
| Return On Asset | -0.51 | ||||
| Current Valuation | 9.46 M | ||||
| Shares Outstanding | 4.29 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 2.31 % | ||||
| Number Of Shares Shorted | 41.24 K | ||||
| Price To Earning | 8.69 X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 2.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (17.53) | Return On Assets (0.51) | Return On Equity (2.70) |
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.